Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Tuberculosis | Research article

Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland

Authors: Eileen Sweeney, Darren Dahly, Nahed Seddiq, Gerard Corcoran, Mary Horgan, Corinna Sadlier

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single infectious agent. Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for TB, yet its efficacy remains debated with variations in vaccine sub-strains, policies, and practices observed across the world. Three BCG vaccination policies were implemented across adjoining regions in the South West of Ireland from 1972; neonatal vaccination (vaccinated Region-A), vaccination of children aged 10–12 years (vaccinated Region-B) and no vaccination (unvaccinated Region-C). The aim of this study is to examine the impact of different BCG vaccination policies on incidence of TB disease in the South of Ireland over a 13-year period.

Methods

Cases of active TB disease from 2003 to 2016 were identified through surveillance data. Residential addresses for each case were geocoded using the Google Maps API. Addresses were linked to 2011 census population data and to Local Health Offices BCG coverage data for study regions A-C. A steady-state population was assumed to calculate the 13-year incidence of TB disease. Using SatScan (v9.4.4), spatial clusters were identified at a small area level with the spatial scan statistic based on the discrete Poisson probability distribution.

Results

Of 621 TB disease cases identified, 510 could be linked to the study area based on the reported addresses. The median age was 42 years (range 4 months - 94 years), 65% male and 66% Irish born. The incidence of TB disease was higher in the unvaccinated population, region-C 132/100,000 (95% CI 116–150) versus vaccinated region-A 56/100,000 (95%CI 45–69) and region-B 44/100,000 (95%CI 29–63). A spatial cluster analysis identified a single high-risk cluster in region -C where the relative risk (vs. the areas outside of the cluster) was 4.94 (95% CI 4.03 to 5.96).

Conclusion

Our study demonstrates significant regional variation in the incidence of TB in demographically similar populations based on BCG vaccination policy. This observation is particularly noteworthy in a country with low TB disease incidence such as Ireland. These findings strengthen existing data demonstrating efficacy of BCG vaccination for primary prevention of TB disease.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Braima O, Rigney A, Ryan CA, Murphy C. Uptake of newly introduced universal BCG vaccination in newborns. Ir Med J. 2010;103(6):187–8.PubMed Braima O, Rigney A, Ryan CA, Murphy C. Uptake of newly introduced universal BCG vaccination in newborns. Ir Med J. 2010;103(6):187–8.PubMed
4.
go back to reference Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ (Clinical research ed). 2014;349:g4643. Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ (Clinical research ed). 2014;349:g4643.
5.
go back to reference Stýblo K, Danková D, Drápela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia. Report for the first 4 years of the study (1961-64). Bull World Health Organ. 1967;37(6):819–74.PubMedPubMedCentral Stýblo K, Danková D, Drápela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia. Report for the first 4 years of the study (1961-64). Bull World Health Organ. 1967;37(6):819–74.PubMedPubMedCentral
6.
go back to reference Dara M, Acosta C, Rusovich V, Zellweger J-P, Centis R, Battista Migliori G. Bacille Calmette-Guérin vaccination: The current situation in Europe, 2014. Dara M, Acosta C, Rusovich V, Zellweger J-P, Centis R, Battista Migliori G. Bacille Calmette-Guérin vaccination: The current situation in Europe, 2014.
7.
go back to reference Kelly P, McKeown D, Clancy L. Neonatal BCG vaccination in Ireland: evidence of its efficacy in the prevention of childhood tuberculosis. Eur Respir J. 1997;10(3):619–23.PubMed Kelly P, McKeown D, Clancy L. Neonatal BCG vaccination in Ireland: evidence of its efficacy in the prevention of childhood tuberculosis. Eur Respir J. 1997;10(3):619–23.PubMed
8.
go back to reference Usher C, Adams R, Schmitz S, et al. Evaluating the neonatal BCG vaccination programme in Ireland. Archives of public health = archives belges de sante. publique. 2016;74:28. Usher C, Adams R, Schmitz S, et al. Evaluating the neonatal BCG vaccination programme in Ireland. Archives of public health = archives belges de sante. publique. 2016;74:28.
9.
go back to reference Teljeur C, Moran PS, Harrington P, et al. Economic evaluation of selective neonatal BCG vaccination of high-risk infants in Ireland. Pediatr Infect Dis J. 2018. Teljeur C, Moran PS, Harrington P, et al. Economic evaluation of selective neonatal BCG vaccination of high-risk infants in Ireland. Pediatr Infect Dis J. 2018.
13.
15.
go back to reference Tu HA, Vu DH, Rozenbaum M, J Woerdenbag H, Postma M. A review of the literature on the economics of vaccination against TB, 2012.CrossRef Tu HA, Vu DH, Rozenbaum M, J Woerdenbag H, Postma M. A review of the literature on the economics of vaccination against TB, 2012.CrossRef
Metadata
Title
Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland
Authors
Eileen Sweeney
Darren Dahly
Nahed Seddiq
Gerard Corcoran
Mary Horgan
Corinna Sadlier
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4026-z

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.